Private equity giant Blackstone Inc. ( BX ) is reportedly close to finalizing a deal to sell Alinamin Pharmaceutical, a Japanese supplement maker, to North Asian buyout fund MBK Partners for 350 billion yen ($2.17 billion).

The agreement is anticipated to be finalized shortly, reported Reuters, citing a person familiar with the matter.

Also Read: Private Equity Giant Blackstone Targets Japanese Market, Anticipates ‘Accelerated Growth’: Report

According to the Nikkei, MBK plans to leverage its expertise in consumer goods acquisitions to enhance Alinamin’s value. Following the Blackstone deal, the company established a unit in Taiwan and expanded its international sales efforts.

Last month, Blackstone stated it is collaborating with financial advisers on a potential sale of Tokyo-based Alinamin, which could be valued at roughly ¥300 billion ($1.9 billion).

Notably, Blackstone acquired Alinamin from Takeda Pharmaceutical Company ( TAK ) in 2020.

Recently, the company reportedly agreed to purchase a 55.1% stake in Japanese e-comics provider Infocom Corp. for about ¥260 billion ($1.66 billion).

Blackstone stock has gained more than 29% in the last 12 months. Investors can gain exposure to the stock via Invesco Global Listed Private Equity ETF ( PSP )  and EA Series Trust WHITEWOLF Publicly Listed Private Equity ETF .

Price Action: BX shares are down 0.60% at $121.50 premarket at the last check Tuesday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Image via Shutterstock